Evaluating the effects of "triple therapy" with inhaled corticosteroids, long-acting beta2-agonists, and leukotriene modifiers in asthma.
Currie
Graeme P
GP
Lee
Daniel K C
DK
Menzies
Daniel
D
Lipworth
Brian J
BJ
D000085:Acetates / Q000008:administration & dosage* / Q000627:therapeutic use; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage* / Q000627:therapeutic use; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage* / Q000627:therapeutic use; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy*; D003521:Cyclopropanes; D004359:Drug Therapy, Combination; D006801:Humans; D020024:Leukotriene Antagonists / Q000008:administration & dosage* / Q000627:therapeutic use; D010366:Peak Expiratory Flow Rate / Q000187:drug effects; D011804:Quinolines / Q000008:administration & dosage* / Q000627:therapeutic use; D013440:Sulfides
D000085:Acetates; D000305:Adrenal Cortex Hormones; D000318:Adrenergic beta-Agonists; D018927:Anti-Asthmatic Agents; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; C093875:montelukast